Cannabidiol (CBD) is a component of Cannabis sativa that has a broad spectrum of potential therapeutic effects in neuropsychiatric and other disorders. However, few studies have investigated the possible interference of CBD on the sleep-wake cycle. The aim of the present study was to evaluate the effect of a clinically anxiolytic dose of CBD on the sleep-wake cycle of healthy subjects in a crossover, double-blind design. Twenty-seven healthy volunteers that fulfilled the eligibility criteria were selected and allocated to receive either CBD (300 mg) or placebo in the first night in a double-blind randomized design (one volunteer withdrew from the study). In the second night, the same procedure was performed using the substance that had not been administered in the previous occasion. CBD or placebo were administered 30 min before the start of polysomnography recordings that lasted 8 h. Cognitive and subjective measures were performed immediately after polysomnography to assess possible residual effects of CBD. The drug did not induce any significant effect (p > 0.05). Different from anxiolytic and antidepressant drugs such as benzodiazepines and selective serotonin reuptake inhibitors, acute administration of an anxiolytic dose of CBD does not seem to interfere with the sleep cycle of healthy volunteers. The present findings support the proposal that CBD do not alter normal sleep architecture. Future studies should address the effects of CBD on the sleep-wake cycle of patient populations as well as in clinical trials with larger samples and chronic use of different doses of CBD. Such studies are desirable and opportune.
One of the strongest nutraceutical CBD oils is called Charlotte’s Web, with a 50mg dose. Charlotte’s Web is produced in Colorado by the Stanley Brothers, and named after Charlotte Figi, a girl who became famous in the US after her frequent seizures, brought on by the rare Dravet syndrome, were greatly reduced when she started taking CBD oil aged five. The company makes THC products too and is extremely successful, having just offered shares on the Canadian securities exchange, raising about $100m.
Stephanie Kahn, who with her husband, Jeffrey, runs the Takoma Wellness Center, a medical marijuana dispensary in Northwest Washington, says that about half of her 1,200 patients use CBD-rich products. Her dispensary offers several strains of high-CBD cannabis as well as CBD oil, with different ratios of CBD and THC, each of which she recommends for particular conditions. “We get questions about it every day,” she says. “A lot of our patients get relief with this, and a lot of times this works better than pharmaceutical drugs.”
Hemp oil has never been as popular as other marijuana products. With little to no THC, CBD-rich strains of cannabis don’t deliver the pleasant buzz recreational users seek out in marijuana. In the 1970s, however, scientists found that cannabidiol was effective in reducing seizures. The brain’s endocannabinoid system contains receptors that respond to CBD, producing anticonvulsant effects. Being plant-derived and native to the brain’s own chemistry, CBD is therefore one of the most natural options for seizure treatment available today. Still, not many people took interest in CBD until 2013, when a CNN documentary special, Weed, hosted by the network’s chief medical correspondent, Dr. Sanjay Gupta, highlighted CBD’s effectiveness in combating seizures. Since then, demand for hemp oil products has exploded.
The ACMPR requires that all Licensed Producers display total levels of potential THC and CBD on their product labels. Total potential THC is the total amount of THC available when all THCa (tetrahydrocannabinolic acid) is decarboxylated. Total potential CBD is the total of CBD available when all the CBDa (Cannabidiolic acid) is decarboxylated. Learn more about decarboxylation here.
A research conducted by Ethan B Russo, GW Pharmaceuticals, WA, USA, suggests that CBD oil interacts with the protein cells in the body and sends chemical signals to your brain and immune system through a number of stimuli. This helps the cells positively respond to chronic pain. This oil is regularly suggested for people with inflammation and back pain because of its painkilling quality.
Results from the study indicated that CBD administration increased neuronal proliferation and neurogenesis in the hippocampal region. It is also thought that CBD’s modest affinity for cannabinoid receptors CB1 and CB2 may contribute to hippocampal neurogenesis. Stimulation of the CB1/CB2 receptor sites upregulates endocannabinoid signaling and leads to neuronal growth.
Research reveals that CBD can is an effective treatment option with a wide array of natural health properties. Studies are still ongoing about the other positive characteristics of CBD, but it has been proven that consumption of this compound is relatively safe. Just as important, CBD is also legal in all 50 states without a prescription. Cannabis oil, however, does not enjoy the same legal umbrella due to its THC content and psychoactive properties. Therefore, users who purchase or use THC or Cannabis oil in states where marijuana is illegal may be breaking the law.
Tolerance: It is possible that someone who uses CBD oil often could become tolerant to its effects. This is because no drug is capable of bypassing the endogenous homeostatic mechanisms of the human body. If something were capable of doing so, people could remain on an anxiolytic and/or antidepressant for an indefinite period of time without any decreased efficacy. Unfortunately, it is likely that if used too frequently, tolerance will ensue and an individual will require greater doses to maintain a therapeutically anxiolytic effect.
A 2013 case report conducted in Canada evaluated the beneficial effects of cannabis oil on a 14-year-old female patient diagnosed with acute lymphoblastic leukemia, also known as ALL. For this particular patient, a standard bone marrow transplant, aggressive chemotherapy and radiation therapy were revoked, with treatment being deemed a failure after 34 months. She was extremely ill and severely underweight at this time.
Because of this classification, it's not easy for researchers to get their hands on the drug. "That's not to say you can't do it, but there are hoops you need to jump through that can be a pain, which may deter researchers from going into this space," Bonn-Miller said. "Relatively speaking, it's a small group of people in the U.S. that do research on cannabinoids in humans."
Medical Disclaimer: Statements in any video or written content on this site have not been evaluated by the FDA. If you are pregnant, nursing, taking medications, or have a medical condition, consult your physician before using this product. Representations regarding the efficacy and safety of CBD oil have not been evaluated by the Food and Drug Administration. The FDA only evaluates foods and drugs, not supplements like these products. These products are not intended to diagnose, prevent, treat, or cure any disease. The material on this site is provided for informational purposes only and is not medical advice. Always consult your physician before beginning any supplement program.
Copyright © thejoyfullotus.com